References
- Hebenstreit K, Iacobelli S, Leiblein S, et al. Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia. Leuk Lymphoma 2014;55:1274–1280.
- Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101–1110.
- Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369: 32–42.
- Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370: 997–1007.
- Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725–733.
- Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013;122:3723–3734.
- Stilgenbauer S, Chang B, Furman R, et al. Tumor genomic profiling reveals mechanisms of resistance to BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) [abstract]. Presented at the 15th iwCLL, 6–8 September 2013, Cologne, Germany.
- Furman RR, O’Brien S, Flinn IW, et al. The Bruton tyrosine kinase (BTK) inhibitor ibrutinib promotes a high frequency of durable response in relapsed/ refractory and older treatment naïve CLL patients: final results of a phase Ib/II study [abstract]. Presented at the15th iwCLL, 6–8 September 2013, Cologne, Germany.
- Godley LA, van Besien K. The next frontier for stem cell transplantation: finding a donor for all. JAMA 2010;303:1421–1422.
- Muffly LS, Boulukos M, Swanson K, et al. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant 2013;19:429–434.
- Flandrin-Gresta P, Callanan M, Nadal N, et al. Transmission of leukemic donor cells by allogeneic stem cell transplantation in a context of familial CLL: should we screen donors for MBL? Blood 2010;116:5077–5078.